Gefitinib

FDA Approved: * September 23, 2022
Pharm Company: * APOTEX
Category: Cancer

Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva. It is on the World Health Organization's List of Essential Med... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Gefitinib 250 mg Oral Tablet, Film Coated
NDC: 0480-4053
Labeler:
Teva Pharmaceuticals, Inc.
Gefitinib 250 mg Oral Tablet, Coated
NDC: 50742-366
Labeler:
Ingenus Pharmaceuticals, LLC
Gefitinib 250 mg Oral Tablet
NDC: 60505-4512
Labeler:
Apotex Corp.
Gefitinib 250 mg Oral Tablet, Coated
NDC: 67184-0531
Labeler:
Qilu Pharmaceutical Co., Ltd.
Gefitinib 250 mg Oral Tablet, Film Coated
NDC: 69339-168
Labeler:
Dash Pharmaceuticals LLC

Related Brands

Drugs with the same active ingredients